[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best-performing stocks tend to have an RS Rating north of 80 as they begin their biggest runs.
Bio Rad Labs is trying to complete a flat base with a 273.97 entry . See if the stock can break out in volume at least 40% higher than normal. It's a later-stage pattern, and investors should be aware that those involve more risk.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -72% to 47%. Revenue rose from -2% to 5%.
The company holds the No. 18 rank among its peers in the Medical-Research Equipment/Services industry group. PRA Health Sciences ( PRAH ), Illumina ( ILMN ) and Catalent ( CTLT ) are among the top 5 highly rated stocks within the group.